OCULAR MANIFESTATIONS IN A PATIENT WITH HIDRADENITIS SUPPURATIVA: A CASE STUDY.

Q4 Medicine
Georgian medical news Pub Date : 2025-01-01
H Al Dhaheri, M Khan
{"title":"OCULAR MANIFESTATIONS IN A PATIENT WITH HIDRADENITIS SUPPURATIVA: A CASE STUDY.","authors":"H Al Dhaheri, M Khan","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Patients with chronic inflammatory skin disease called hidradenitis suppurativa (HS), which can also produce systemic comorbidities, show ocular symptoms. Although HS has dermatological roots, if left untreated it can cause major ocular issues like dry eye syndrome and corneal neovascularization, therefore affecting eyesight.</p><p><strong>Case description: </strong>Our patient, a 19-year-old man with corneal neovascularization, scarring, bilateral dry eye disease, uncontrolled HS, and other medical disorders, after a year of therapy with adalimumab failed to sufficiently control the illness, secukinumab (300 mg monthly) and concomitant oral doxycycline (100 mg twice daily) were prescribed to reduce inflammation and prevent subsequent infections. As shown by ophthalmologic findings, bilateral corneal neovascularization, stromal infiltrates, and chronic inflammation helped to explain ocular discomfort and reduced quality of life. Both eyes maintained visual acuity at 6/6 even though corneal scarring could cause future damage. Management and treatment: A multidisciplinary team under management of the patient comprised ophthalmology and dermatology doctors. Using continuous systemic treatment, management of HS flares and ocular inflammation is the ocular treatment included Tobradex, Lumify, artificial tears; more modern treatments like anti-VEGF therapy were under consideration for cases of progressive neovascularization.</p><p><strong>Conclusion: </strong>As this case shows, a multidisciplinary approach is absolutely essential when tackling HS including the eyes. Early diagnosis and tailored treatment plans allow one to improve patient outcomes, maintain visual function, and minimize repercussions. More study is needed to better grasp the pathophysiology of HS-related ocular problems and create more sensible treatment plans.</p>","PeriodicalId":12610,"journal":{"name":"Georgian medical news","volume":" 358","pages":"31-34"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Georgian medical news","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Patients with chronic inflammatory skin disease called hidradenitis suppurativa (HS), which can also produce systemic comorbidities, show ocular symptoms. Although HS has dermatological roots, if left untreated it can cause major ocular issues like dry eye syndrome and corneal neovascularization, therefore affecting eyesight.

Case description: Our patient, a 19-year-old man with corneal neovascularization, scarring, bilateral dry eye disease, uncontrolled HS, and other medical disorders, after a year of therapy with adalimumab failed to sufficiently control the illness, secukinumab (300 mg monthly) and concomitant oral doxycycline (100 mg twice daily) were prescribed to reduce inflammation and prevent subsequent infections. As shown by ophthalmologic findings, bilateral corneal neovascularization, stromal infiltrates, and chronic inflammation helped to explain ocular discomfort and reduced quality of life. Both eyes maintained visual acuity at 6/6 even though corneal scarring could cause future damage. Management and treatment: A multidisciplinary team under management of the patient comprised ophthalmology and dermatology doctors. Using continuous systemic treatment, management of HS flares and ocular inflammation is the ocular treatment included Tobradex, Lumify, artificial tears; more modern treatments like anti-VEGF therapy were under consideration for cases of progressive neovascularization.

Conclusion: As this case shows, a multidisciplinary approach is absolutely essential when tackling HS including the eyes. Early diagnosis and tailored treatment plans allow one to improve patient outcomes, maintain visual function, and minimize repercussions. More study is needed to better grasp the pathophysiology of HS-related ocular problems and create more sensible treatment plans.

化脓性汗腺炎的眼部表现:一个病例研究。
背景:慢性炎症性皮肤病化脓性汗腺炎(HS)也可产生全身合并症,患者表现为眼部症状。虽然HS有皮肤病的根源,但如果不及时治疗,它会引起严重的眼部问题,如干眼综合征和角膜新生血管,从而影响视力。病例描述:我们的患者是一名19岁的男性,患有角膜新生血管、瘢痕形成、双侧干眼病、不受控制的HS和其他内科疾病,在阿达木单抗治疗一年后未能充分控制病情,我们开了secukinumab(每月300毫克)和同时口服强力霉素(100毫克,每日两次)以减少炎症和预防后续感染。眼科检查结果显示,双侧角膜新生血管、间质浸润和慢性炎症有助于解释眼部不适和生活质量下降。两只眼睛的视力都保持在6/6,尽管角膜疤痕可能会造成未来的损害。管理和治疗:由眼科和皮肤科医生组成的多学科团队对患者进行管理。采用连续的系统治疗方法,对HS耀斑和眼部炎症进行管理,眼部治疗包括Tobradex、Lumify、人工泪液;更现代的治疗方法,如抗vegf治疗,正在考虑治疗进行性新血管形成的病例。结论:正如本病例所示,在治疗包括眼睛在内的HS时,多学科的方法是绝对必要的。早期诊断和量身定制的治疗计划可以改善患者的预后,保持视觉功能,并最大限度地减少不良反应。需要更多的研究来更好地掌握hs相关眼病的病理生理,制定更合理的治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Georgian medical news
Georgian medical news Medicine-Medicine (all)
CiteScore
0.60
自引率
0.00%
发文量
207
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信